Loading: 100%
Profit & Loss StatementP&L data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reasons:
- It is not known how cost items are reported in the original P&L
- Not all line items from the original statement have been associated with a standardised figure (22 items missing)
No data available for the selected time periods
in million USD FY '08FY '09FY '10FY '11FY '12FY '13FY '14FY '15
Net product revenues
252
316
370
438
496
538
738
885
Collaborative agreement revenues
39
2
1
0
2
4
2
1
Royalty, license and other revenues
6
7
6
3
2
6
9
4
Total revenues
296
325
376
441
501
548
749
890
Cost of sales (excludes amortization of intangible assets)
53
66
70
84
92
88
122
152
Research and development
93
115
147
214
302
355
462
635
Selling, general and administrative
107
124
152
175
198
235
302
402
Intangible asset amortization and contingent consideration
4
3
6
1
19
25
24
-18
Impairment of intangible asset
0
0
0
0
0
1
0
199
Gain on sale of intangible asset
0
0
0
0
0
0
-68
-369
Total operating expenses
257
308
376
475
611
704
842
1,001
Loss from operations
40
16
1
-34
-110
-156
-93
-111
Equity in the loss of BioMarin/Genzyme LLC
-2
-3
-3
-2
-1
-1
-1
-1
Interest income
16
5
4
3
3
3
6
5
Interest expense
-16
-14
-11
-8
-8
-10
-37
-38
Debt conversion expense
0
0
-14
-2
0
-13
-1
0
Impairment loss on equity investments
-4
-6
0
0
0
0
0
0
Net gain from sale of investments
0
2
1
0
0
0
0
0
Other income (expense)
0
0
0
0
-2
1
0
-9
Loss before income taxes
33
1
-21
-44
-118
-177
-125
-155
Provision for (benefit from) income taxes
3
1
-227
10
-4
0
9
17
Net loss
31
0
206
-54
-114
-176
-134
-172
Remarks
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Feb 26, 2013 n/a
calculated values,
restated on Feb 26, 2014 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Feb 29, 2016 n/a
calculated values,
restated on Feb 29, 2016 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
Balance SheetBS data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (32 items missing)
No data available for the selected time periods
in million USD FY '08FY '09FY '10FY '11FY '12FY '13FY '14FY '15
Assets
Cash and cash equivalents
n/a
167
88
46
181
569
875
397
Short-term investments
n/a
134
186
149
267
216
70
196
Accounts receivable, net
n/a
74
87
105
109
118
144
165
Inventory
n/a
79
110
130
129
163
199
272
Current deferred tax assets
n/a
0
0
21
32
31
0
0
Other current assets
n/a
15
34
19
26
42
109
60
Total current assets
n/a
468
504
470
743
1,137
1,398
1,090
Investment in BioMarin/Genzyme LLC
n/a
0
1
1
1
1
0
0
Long-term investments
n/a
170
128
94
116
268
98
426
Property, plant and equipment, net
n/a
199
222
269
284
319
524
704
Intangible assets, net
n/a
41
104
180
163
163
157
684
Goodwill
n/a
24
53
52
52
54
54
197
Deferred tax assets
n/a
0
236
225
189
145
191
220
Other assets
n/a
15
14
15
20
156
55
409
Total assets
n/a
917
1,263
1,306
1,568
2,244
2,475
3,729
Liabilities and owners' equity
Deferred revenue
n/a
0 86000
0 0
0 0
0 0
0 0
0 0
0 0
Accounts payable and accrued liabilities
n/a
78 78068000
84 83844000
94 94125000
147 147068000
183 183271000
232 231844000
393 392511000
Convertible debt
n/a
0 0
0 0
0 0
23 23365000
0 0
0 0
0 0
Short-term contingent acquisition consideration payable
n/a
0 0
0 0
0 0
0 0
0 0
4 3895000
53 52946000
Total current liabilities
n/a
78 78154000
84 83844000
94 94125000
170 170433000
183 183271000
236 235739000
445 445457000
Long-term convertible debt, net
n/a
497 497083000
378 377521000
348 348329000
325 324859000
656 655566000
643 642902000
662 662286000
Long-term contingent acquisition consideration payable
n/a
0 0
0 0
33 33059000
31 30618000
31 30790000
39 38767000
33 32663000
Long-term deferred tax liabilities
n/a
0 0
0 0
37 37155000
0 0
0 0
0 0
144 143527000
Other long-term liabilities
n/a
20 19741000
84 84001000
20 19993000
27 26674000
33 33392000
30 30077000
45 44588000
Total liabilities
n/a
595 594978000
545 545366000
533 532661000
553 552584000
903 903019000
947 947485000
1,329 1328521000
Common stock
n/a
0 101000
0 111000
0 115000
0 126000
0 144000
0 149000
0 162000
Additional paid-in capital
n/a
900 899950000
1,090 1090188000
1,197 1197082000
1,562 1561890000
2,059 2059101000
2,360 2359744000
3,415 3414837000
Company common stock held by Nonqualified Deferred Compensation Plan
n/a
-2 -1715000
-2 -1965000
-4 -3935000
-7 -6603000
-7 -7421000
-10 -9695000
-14 -13616000
Accumulated other comprehensive income
n/a
1 933000
0 188000
5 4887000
0 -202000
5 5018000
27 27466000
21 21033000
Accumulated deficit
n/a
-577 -577084000
-371 -371265000
-425 -425101000
-539 -539448000
-716 -715801000
-850 -849770000
-1,022 -1021569000
Total stockholders’ equity
n/a
322 322185000
717 717257000
773 773048000
1,016 1015763000
1,341 1341041000
1,528 1527894000
2,401 2400847000
Total liabilities and stockholders’ equity
n/a
917 917163000
1,263 1262623000
1,306 1305709000
1,568 1568347000
2,244 2244060000
2,475 2475379000
3,729 3729368000
Remarks restated on n/a restated on Nov 30, -1 n/a restated on Feb 22, 2012 n/a restated on Feb 26, 2013 n/a restated on Feb 26, 2014 n/a restated on Mar 2, 2015 n/a restated on Feb 29, 2016 n/a restated on Nov 30, -1 n/a
Cash Flow StatementCF data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (54 items missing)
No data available for the selected time periods
in million USD FY '08FY '09FY '10FY '11FY '12FY '13FY '14FY '15
Net loss
31
0
206
-54
-114
-176
-134
-172
Depreciation and amortization expense
18
21
28
35
44
36
46
47
Non-cash interest expense
4
3
0
1
1
6
27
28
Accretion of discount on investments
-6
1
4
4
4
6
7
2
Stock-based compensation expense
28
36
38
44
47
64
86
112
Gain on sale of intangible asset
0
0
0
0
0
0
-68
-369
Gain on termination of leases
0
0
0
0
0
0
-10
0
Equity in the loss of BioMarin/Genzyme LLC
2
3
3
2
1
0
0
0
Loss on conversion of convertible promissory note
0
0
0
0
0
0
0
0
Gain on sale of equity investment
0
-2
-1
0
0
0
0
-3
Impairment of assets
4
6
0
0
7
1
0
212
Deferred income taxes
0
0
-231
4
-10
-9
-26
-77
Excess tax benefit from stock option exercises
-1
0
-1
0
0
-1
-1
-2
Unrealized foreign exchange gain on forward contracts
0
1
-4
7
-7
-1
-1
-20
Non-cash changes in the fair value of contingent acquisition consideration payable
0
0
4
-2
9
10
12
-28
Debt conversion expense
0
0
14
2
0
13
1
0
Other
0
0
0
0
2
1
5
2
Accounts receivable, net
-37
-19
-13
-18
-4
-9
-26
-16
Inventory
-14
-6
-31
-20
1
-21
-22
-51
Other current assets
-41
37
3
3
-4
-12
-2
26
Other assets
1
-1
-5
-1
-4
4
-7
-3
Accounts payable and accrued liabilities
7
8
2
10
37
20
38
90
Other long-term liabilities
0
1
2
2
6
10
3
1
Deferred revenue
-5
0
0
0
0
0
0
0
Net cash used in operating activities
-9
88
19
18
18
-57
-72
-222
Purchases of property, plant and equipment
-56
-90
-49
-73
-45
-65
-117
-228
Funds held in escrow for the purchase of real property
0
0
0
0
0
-117
0
0
Deposit on purchase of PKU rights
0
0
0
0
0
0
0
-372
Maturities and sales of investments
761
475
206
282
238
289
808
425
Purchase of available-for-sale investments
-733
-446
-222
-215
-382
-395
-507
-873
Proceeds from sale of intangible asset
0
0
0
-81
0
0
68
410
Business acquisitions, net of cash acquired
0
-18
-33
0
0
-10
0
-538
Investments in BioMarin/Genzyme LLC
-2
-2
-4
-2
-2
0
0
0
Distributions from BioMarin/Genzyme LLC
17
0
0
0
0
0
0
0
Investment in convertible promissory note
-6
0
0
0
-5
0
-52
-3
Other
0
0
0
0
0
-1
-3
0
Net cash provided by (used in) investing activities
-19
-80
-101
-90
-196
-299
196
-1,180
Proceeds from exercises of stock options and the ESPP
28
11
33
34
83
73
80
63
Taxes paid related to net share settlement of equity awards
0
0
0
0
-2
-6
-8
-23
Proceeds from convertible senior note offering, net
0
0
0
0
0
726
0
0
Purchase of capped call share options
0
0
0
0
0
-30
0
0
Proceeds from public offering of common stock, net
0
0
0
0
235
0
117
888
Excess tax benefit from stock option exercises
1
0
1
0
0
1
1
2
Payments for debt conversion
0
0
-14
-2
0
-13
-1
0
Payment on maturity of 2013 convertible note
0
0
0
0
0
0
0
0
Repayment of acquisition obligation
-7
-74
0
0
0
0
0
0
Repayment of capital lease obligations
0
0
0
-1
0
0
0
0
Payment of contingent acquisition consideration payable
0
-1
-16
-2
-4
-3
-5
0
Other
0
0
0
0
-1
-1
0
-2
Net cash provided by financing activities
23
-64
4
29
312
747
186
928
Effect of exchange rate changes on cash
0
0
0
0
0
-2
-3
-5
Net increase (decrease) in cash and cash equivalents
-5
-56
-79
-42
134
388
307
-478
Increase in asset retirement obligation
0
0
0
3
0
0
0
0
Remarks
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Feb 26, 2013 n/a
calculated values,
restated on Feb 26, 2014 n/a
calculated values,
restated on Mar 2, 2015 n/a
calculated values,
restated on Feb 29, 2016 n/a
calculated values,
restated on Feb 29, 2016 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,